Last reviewed · How we verify
EN3267
EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation.
EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation. Used for Immunoglobulin A nephropathy (IgAN).
At a glance
| Generic name | EN3267 |
|---|---|
| Also known as | Fentanyl |
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | C5a receptor antagonist |
| Target | C5aR1 (C5a receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
EN3267 selectively inhibits the C5a receptor (C5aR1), a key component of the complement cascade that drives innate immune activation and inflammation. By blocking C5a signaling, the drug reduces chemotaxis and activation of neutrophils and other immune cells, thereby dampening excessive inflammatory responses. This mechanism is intended to treat complement-mediated inflammatory and autoimmune diseases.
Approved indications
- Immunoglobulin A nephropathy (IgAN)
Common side effects
- Nasopharyngitis
- Headache
- Diarrhea
Key clinical trials
- Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients (PHASE3)
- Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EN3267 CI brief — competitive landscape report
- EN3267 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI